Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE SurgiQuest, Inc.
MILFORD, Conn., May 23, 2014 /PRNewswire/ -- SurgiQuest, Inc. ("SurgiQuest", the "Company"), a leading provider of innovative access technologies for minimally invasive surgery (MIS), today announced that its AirSeal® System was highlighted on multiple occasions during the Annual Meeting of the American Urological Association in Orlando, Florida.
Three live surgical procedures featuring AirSeal were broadcast before a large audience in The Orange County Convention Center's Chapin Theater on Saturday, May 17th, including a Robotic Sacrocolpopexy by Wesley White, MD at the University of Tennessee Medical Center, a Robotic Partial Nephrectomy by Dipen Parekh, MD at the University of Miami Hospital, and a Robotic Ureteral Reimplantation performed by Michael Stifelman, MD and NYU Langone Medical Center in New York, NY. This was the second consecutive year that AirSeal was highlighted in live surgical procedures during AUA's Annual Meeting.
"AirSeal has become an essential technology for me when performing any robotic surgical procedures," said Dipen Parekh, MD, the Professor and Chairman of the Department of Urology and the Director of Robotic Surgery at the University of Miami's Miller School of Medicine. "The ability to use suction without losing pneumoperitoneum is a significant surgical advantage."
In addition to the live surgical procedures, data from the University of California, Irvine Medical Center's prospective, randomized AirSeal trial was presented on Sunday, May 18th. Data from the study entitled "Prospective Randomized Study Comparing the Physiologic Effects of Valveless Insufflation and Conventional Laparoscopic Insufflator" demonstrated statistically significant improvements in both the stability of pneumoperitoneum and key respiratory and hemodynamic parameters.
"We were excited to present our study data as it clearly demonstrated several of the clinical advantages of the AirSeal System," said Jaime Landman, MD, who is the Chairman of the Department of Urology and Professor at the University of California, Irvine. "It was also great to see that our data was so very consistent with the wonderful outcomes seen in the live cases here at this year's AUA meeting."
SurgiQuest's patented AirSeal Access System optimizes the laparoscopic environment and provides unparalleled stability in the abdominal cavity during MIS. Unlike conventional insufflation and trocar systems, the Company's breakthrough integrated platform ensures stable pneumoperitoneum, continuously evacuates smoke and plume when energized medical devices such as electro-cautery, laser or ultrasound are used, and provides valve-free access to the abdominal cavity during both robotic and laparoscopic surgical procedures. Clinical evidence shows that the AirSeal system produces superior results in terms of reduced post-operative pain, lower intra-abdominal pressure and improved hemodynamic and respiratory parameters.
SurgiQuest, Inc. is a privately held venture-backed company, founded in May 2006. The Company develops, manufactures and markets innovative access technologies for minimally invasive surgery. SurgiQuest's patented AirSeal® System provides unprecedented access to the abdominal cavity during minimally invasive surgery ("MIS"). Unlike conventional insufflation and trocar systems, the Company's breakthrough integrated platform assures stable pneumoperitoneum, continuously evacuates smoke and plume when energized medical devices such as electrocautery, laser or ultrasound are used, and provides valve-free access to the abdominal cavity during both laparoscopic and robotic surgical procedures. Additional information about SurgiQuest products can be found at www.surgiquest.com.
©2012 PR Newswire. All Rights Reserved.